201 results about "Human glioma" patented technology

The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signaling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin / paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targeting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.

The invention provides a human brain glioma cell line and an establishing method and application thereof. The human brain glioma cell line is preserved in China Center for Typical Culture Collection with an accession number of CCTCC No. C201115. The human brain glioma cell line is established by subjecting brain glioma cells originated from a clinic specimen to primary culture and subculture, can be directly used for in vitro drug screening or generation of human brain glioma in mammals and is used for establishing a human brain glioma animal model and screening candidate drugs used for treating human brain glioma. The human brain glioma cell line has stable properties, can realize stable multiple passages and maintain stable properties even after in vitro passage to the 50th generation; pathogenesis of human brain glioma, drug susceptibility, transitivity and other related characteristics can be analyzed in vitro and in vivo, so two correlated in-vitro and in-vivo anti-brain glioma drug screening platforms can be established, and novel experimental materials closer to clinic oncobiological characteristics are provided for research on human brain glioma.

The invention relates to a method for preparing an RGD peptide targeted ultra-small ferriferrous oxide MRI positive nanoprobe. The method comprises the steps of: conducting a one-step solvothermal synthesis method to obtain surface sodium citrate stabilized ultra-small Fe3O4 nanoparticles, then modifying NH2-PEG-RGD to the nanoparticle surface to obtain the RGD targeted ultra-small ferriferrous oxide MRI positive molecular probe. The PEG-RGD modified ultra-small ferriferrous oxide nanoprobe has long cycle time in mice, and realizes targeting T1-weighted enhancement MRI on the surface of cancer cells with alphavbeta3 integrin high expression (U87MG cells, human brain glioma cells) and subcutaneously transplanted tumor on animal level and cellular level. The Fe3O4 nanoparticles prepared by the invention can be in stably dispersed in an aqueous solution for a long time, and do not agglomerate. The preparation method provided by the invention has the advantages of simpleness, low cost and potential in industrialization and commercialization.

The invention relates to a marine bacillus and its polypeptide with antitumor activity. The strain is preserved at China Center for Type Culture Collection in Wuhan, and its preservation number is CCTCC M 2013063. A novel marine bacillus polypeptide with anti-tumor activity is obtained from a fermentation product of the strain. By means of an MTT method, the invention finds that the polypeptide has an obvious proliferation inhibition effect on human hepatoma carcinoma cell BEL-7402, human breast cancer cell MCF-7, human glioma cell U251, human non-small-cell lung cancer cell A549 and other tumor cells, has relatively small cytotoxicity on human fibroblast HFL1, and can be applied in drugs treating human liver cancer, gliomas, lung cancer and breast cancer.

The invention relates to the technical field of medicines. The invention relates to the field of biomimetic drugs, in particular to biomimetic drug-loaded nanoparticles targeting brain tumor and a preparation method and application thereof, and particularly relates to adriamycin-loaded polyglutamic acid biomimetic nanoparticles which target brain tumor cells and is coated by human brain glioma U87cell membranes and a preparation method and application thereof in drugs for treating brain tumor diseases. The preparation method of the biomimetic drug-loaded nanoparticles targeting brain tumor comprises the following steps: preparing adriamycin-loaded polyglutamic acid nanoparticles, and coating the surfaces of the nanoparticles with the human brain glioma U87 cell membranes to form the stable biomimetic drug-loaded nanoparticles. Therefore, higher encapsulation efficiency and better slow release performance are realized, the targeting property of the nano drug delivery system is improved, the biomimetic drug delivery nanoparticles penetrating through the blood-brain barrier can be more effectively gathered in a brain tumor area, and the effect of treating brain tumors by chemotherapeutic drugs is improved.

The invention discloses an antisense oligonucleotide which can inhibit the expression of human microRNA-133a and application thereof. The antisense oligonucleotide specificity is combined with the human miR-133a and contains the consecutive nucleotide sequences complementary with the following nucleotide sequence: 5'-UUUGGUCCCCUUCAACCAGCUG-3', especially 5'-CAGCUGGUUGAAGGGGACCAAA-3'. The antisense oligonucleotide can be used as the chimera of ribonucleotides or deoxyribonucleotides or ribonucleotide with deoxyribonucleotide and can modify any nucleotide in the chains. The miR-133a antisense oligonucleotide can effectively inhibit the miR-133a expression in human brain glioma cells, and can inhibit the growth and proliferation of human brain glioma cells, thereby effectively treating braingliomas and other tumors with high miR-133a expression.

The invention belongs to the field of biotechnology and medicine and relates to an application of miR-219, a new marker of human brain glioma. The fact that the expressions of miR-219 in the human brain glioma tissues and cells are obviously reduced is confirmed for the first time, and the facts that miR-219 can directly control Hh-Gli2 and Pdgfra signal paths during early development of the neural tube of embryo and occurrence of the brain glioma and can obviously suppress proliferation and infiltration of human glioma cells are confirmed. Further quantitative analysis of clinical brain glioma specimens at different levels shows that miR-219 can serve as the marker for detecting the brain glioma.

The invention relates to an application of anti-sense miRNA (Ribonucleic Acid)-210to the preparation of an anti-cancer drug, in particular to an application of anti-sense miRNA-210. The anti-sense miRNA-210 for preparing the anti-cancer drug belongs to the technical field of biomedical materials. In the application, a miRNA chip is adopted to research the expression situation of three examples of brain glioma miRAN, nine examples of brain glioma samples and four strains of brain glioma cells are verified by a chip result with Northern and q-PCR (Polymerase Chain Reaction) methods and the like, and a result proves that the anti-sense miRNA-210 can obviously lower the invasion capability of the brain glioma cell strains.

The invention a bionic acid-sensitive nano drug as well as a preparation method and an application method thereof. The bionic acid-sensitive nano drug comprises an inner core and an outer shell, wherein the outer shell comprises a targeted modified red blood cell membrane. The bionic acid-sensitive nano drug has immune-free natural biological characteristics, and can greatly prolong in-vivo circulating time of the nano drug; and the inner core comprises a carrier with a sensitive bond on a side chain, and can effectively release the drug to achieve the purpose of targeted treatment of tumors.The preparation method for the bionic acid-sensitive nano drug is simple, is suitable for large-scale production, is suitable for preparing the targeted treatment drug, is preferably suitable for preparing the tumor targeted treatment drug, and is especially suitable for preparing a brain glioma targeted treatment drug, and effectively solves the key problems that the existing nano-drug is short in in-vivo circulating time, has difficulty in crossing BBB, is low intake amount by tumor cells, is low in release at a focus, and the like.

The invention belongs to the biological medicine field, and discloses a targeted boron preparation and a preparation method and application. The target boron preparation comprises polyamidoamine-amine dendrimers, epidermal growth factor receptor antibody and polyhedral boranes, the polyamide amine dendrimers are connected with the epidermal growth factor receptor antibody, and are internally loaded with the polyhedral boranes. The targeted boron preparation is high in boron content, can meet the requirements of BNCT (boron neutron capture therapy) on the boron atom dose, is well targeted to tumor cells, has good stability and low cell toxicity, and can be efficiently uptaken by human glioma U87MG cells of high surface expression EGFR (epidermal growth factor receptor). The target boron preparation can effectively improve the content of boron in orthotopic transplantation tumor nude mice tumor tissues, can significantly prolong orthotopic transplantation tumor nude mice lifetime by neutron irradiation, and is suitable for boron neutron capture therapy for glioma. The preparation method of the targeted boron preparation has the advantages of simple operation, and the prepared targeted boron preparation has good stability.

The invention belongs to the field of biotechnology and discloses a differentially expressed polypeptide in human glioma and a method for encoding a polynucleotide of the polypeptide and producing the peptide by recombinant DNA technology, discloses application of the polypeptide or encoding genes of the polypeptide in preparing a reagent or a regent kit for diagnosing glioma, discloses application of an antagonist resisting the polypeptide in diagnosing and treating diseases, and also discloses the reagent or the regent kit for detecting the glioma.

The present invention provides a recombinant HSV having the ability to specifically kill tumor cells such as human glioma cells in vivo, useful and safe for treating human glioma, etc. and that can easily put to clinical use. A new recombinant HSV, KeM345, is constructed by inserting a γ34.5 gene transcription unit, which is expressed by Musashi1 promoter, into a ribonucleotide reductase gene site of the genome of a herpes simplex virus (HSV) previously attenuated, by means of homologous recombination and obtained as a purified strain. Since KeM345 is a recombinant virus itself, it can not only induce viral proliferation by being transmitted to culture cells but can also induce viral replication equivalent to that of wild-type HSV, showing an excellent cytotoxic effect (cytolytic ability) selectively upon a malignant glioma.

The invention relates to a tumor-targeted multifunctional nano probe with MRI (Magnetic Resonance Imaging) / SPECT (Single Photon Emission Computed Tomography) bimodal images as well as a preparation method and application thereof. The nano probe comprises an MNPs-DSPE-PEG-RGD nano probe composed of Fe@Fe3O4 nano particles and liposome DSPE-PEG-RGD and liposome DSPE-PEG which are coupled on the surface layer of the Fe@Fe3O4 nano particles, and radionuclide I125 can also be marked on the MNPs-DSPE-PEG-RGD nano probe to form an MNPs-DSPE-PEG-RGD-I125 nano probe. The preparation method comprises the following steps: dissolving DSPE-PEG-RGD and DSPE-PEG in an organic solvent, adding an Fe@Fe3O4 nano particle solution, and mixing uniformly to obtain the MNPs-DSPE-PEG-RGD nano probe; and marking with I125 by a chloramine-T method to obtain the MNPs-DSPE-PEG-RGD-I125 nano probe. The prepared MNPs-DSPE-PEG-RGD nano probe is used for MRI of human brain glioma, and the prepared MNPs-DSPE-PEG-RGD-I125 nano probe is used for SPECT. Compared with the prior art, the probe provided by the invention has the advantages of strong targeting property and the like, and multiple molecular imaging probes can be achieved on the same molecule.

The invention discloses an antisense oligonucleotide for suppressing the expression of microRNA (ribose nucleic acid)-145 and application of the antisense oligonucleotide. The antisense oligonucleotide is specifically combined to human miR-145 and comprises a sequence complementary with at least thirteen continuous nucleotides in the nucleotide sequence of 5'-GUCCAGUUUUCCCAGGAAUCCCU-3', and particularly comprises the sequence of 5'-AGGGAUUCCUGGGAAAACUGGAC-3'. The antisense oligonucleotide can be a ribonucleotide, a deoxyribonucleotide or a chimera of the ribonucleotide with the deoxyribonucleotide, and an optional nucleotide in a chain can be modified. The miR-145 antisense oligonucleotide is capable of effectively suppressing the expression of miR-145 in human cerebral glioma cells, and suppressing growth and proliferation of the miR-145, thereby effectively treating cerebral gliomas and other miR-145 highly-expressed tumors.

The instant invention has developed viral vectors encoding a mutant bacterial cytosine deaminase (bCD) gene, which have a higher affinity for cytosine than wild type bCD (bCDwt). The purpose of the present invention was to evaluate cytotoxicity in vitro and therapeutic efficacy in vivo of these vectors in combination with the prodrug 5-FC and ionizing radiation against human glioma. The present study demonstrates that infection with the viral vector expressing the mutant cytosine deaminase gene resulted in increased 5-FC-mediated cell killing, compared with vectors expressing the wild-type gene. Furthermore, a significant increase in cytotoxicity following infection with viral vector expressing the mutant cytosine deaminase gene and radiation treatment of glioma cells in vitro was demonstrated as compared to infection with viral vector expressing the wild-type gene. Animal studies showed significant inhibition of subcutaneous or intracranial tumor growth of D54MG glioma xenografts by the combination of AdbCD-D314A / 5-FC with ionizing radiation as compared with either agent alone, and with AdbCDwt / 5-FC plus radiation. These data indicate that combined treatment with this mutant enzyme / prodrug therapy and radiotherapy provides a promising approach for cancer therapy.

The invention discloses antisense oligonucleotide inhibiting human microRNA-185* from expressing and application thereof. The antisense oligonucleotide is specifically combined with human miR-185*, contains a sequence complementary with at least 13 continuous nucleotides in a 5'-AGGGGCUGGCUUUCCUCUGGUC-3' nucleotide sequence, particularly a sequence of 5'-GACCAGAGGAAAGCCAGCCCCU-3'. The antisense oligonucleotide can be ribonucleotide, deoxyribonucleotide or chimera of both, and can modify any nucleotide in a chain. The miR-185* antisense oligonucleotide effectively inhibits miR-185* in a human glioma cell from expressing, and inhibits the cell from growing and propagating so as to effectively treat human glioma and other miR-185* high-expression tumors.

The invention discloses a method for establishing a green fluorescence BALB / c nude mouse model. The method includes: selecting female C57BL / 6-Tg (CAG-EGFP) mice and male Foxn1nu mice to perform hybrid to acquire F1 child generation hairy fluorescence mice, selecting the female mice, selecting the female mice having sexual maturation and the parental generation male Foxn1nu mice to perform mating (backcross) to acquire an F2 child generation; generating segregation of characters of the F2 child generation, selecting female hairy fluorescence mice and the parental generation male Foxn1nu mice to perform backcross, and completing a backcross cycle; performing the backcross cycle for ten times to acquire an F10 child generation, and establishing the green fluorescence BALB / c nude mouse model. The invention also discloses application of an animal model established by the method to a brain tumor transplanting model. The method uses a homogenous introduction method to establish the new strain model mice which can stably express EGFP, and can lay a firm foundation for human glioma orthotopic transplantation tracking and research on glioma and a micro environment thereof.

The invention discloses antisense oligonucleotide for suppressing expression of human microRNA-328, and application of the antisense oligonucleotide. The antisense oligonucleotide is specifically combined to the human miR-328, comprises sequences complementary with at least 13 continuous nucleotides in a 5'-CUGGCCCUCUCUGCCCUUCCGU-3' nucleotide sequence, particularly a 5'-ACGGAAGGGCAGAGAGGGCCAG-3' sequence. The antisense oligonucleotide can be ribonucleotide, deoxyribonucleotide or chimera of ribonucleotide and deoxyribonucleotide, can modify any nucleotide in a chain. The miR-328 antisense oligonucleotide can effectively suppress the expression of miR-328 in human glioma cells, and suppress the cells from growing and proliferating to effectively treat human glioma and other tumors with high miR-328 expression.

The invention provides application of sinomenine to preparation of a medicament for treating human brain glioma. As proved by experiments, the sinomenine has a function of restraining human-derived glioma U87MG and SF767 cell strains, and the function is improved along with the increase of dose and time. Moreover, the sinomenine can induce the increase of autophagosomes, increase the quantity of autophagic vesicles, prompt the expression increase of human glioma cells LC3B-II, induce autophagic death of human glioma cells, and restrain the growth of U87MG cell xenograft tumors. The sinomenine is a novel and effective glioma-resisting medicament with a great potential, and can be used for preparing a human brain glioma medicament; by adopting the sinomenine, a new way is created for medical treatment of human brain glioma, and the medical application of the sinomenine is expanded.

The invention provides triterpenoid saponin compounds, applications and preparation methods, relating to a compound Phaseoloideside D and a compound Phaseoloideside E obtained by separating from mimosoideae entada phaseoloides leguminous plants and medical applications as well as preparation methods thereof. The in-vitro anti-tumor experiment indicates that the compound Phaseoloideside D and the compound Phaseoloideside E have stronger inhibiting effect on SHG-44 (human glioma), SW480 (colon cancer cells), HepG-2 (liver cancer cells), Ec-109 (esophageal cancer cells) and MCF-7 (human breast cancer cells), can provide a leading compound for preparing new antineoplastics and has key value to develop and use medicinal resources in China.

The invention discloses a human glioma cell line. The preservation number of the human glioma cell line in the China General Microbiological Culture Collection Center is CGMCC NO.16693, and the preservation date is: November 07, 2018. The human glioma cell line of the invention can be stably multi-passaged, has tumorigenicity, can be prepare into a tumor animal model, and can be used for researchand development of human glioma diagnostic reagents, screening of human glioma drugs, and in vitro-studying of human gliomas. Moreover, the present invention differentiates glioma stem cells into glioma cells so as to firstly reduce the number of hetero cells, and after the glioma stem cells are differentiated into the glioma cells, the growth rate is fast, the proliferative ability is strong, andthe characteristics of pathological tissues of brain glioma is retained.

The invention discloses a 6-(5-pyridyl)-1,2,4-triazolopyridine compound, and a preparation method and application thereof. The medical compound is novel in structure, and the synthesis method is easy to realize. The compound has obvious antineoplastic activity and can be used for antineoplastic preparation. Determination of antineoplastic activity on cell proliferation indicates that the synthesized compound has obvious inhibiting action on the proliferation of human colon cancer cells HCT116 and human brain glioma cells U87.

The invention discloses a method for building a fluorescent tumor model in nude mice based on primary cells of human cerebral glioma, and belongs to the field of animal models in the medical fields. The method comprises the following steps: S1, culturing of steady-transferring cells: carrying out cell culturing by adopting an improved DMEM / F12 complete culturing medium, and massively amplifying the primary cells capable of stably expressing luciferase; S2, preparation of cell suspensions: repeatedly cleaning the cells by using the improved DMEM / F12 complete culturing medium, collecting the cell suspensions for subsequent use to ensure that the concentration of the cell suspensions is 6*10<9> cells / mL, and using the suspensions in 40 minutes after the suspensions are prepared; and S3, building of a glioma model of the nude mice: injecting the suspensions in craniums of the nude mice in situ to obtain the mice model capable of stably expressing the luciferase. The fluorescent tumor modelin nude mice based on the human cerebral glioma prepared by adopting the method has the advantages that tumor growth and pathological characteristics of the nude mice are similar to the human cerebral glioma, and growth of the tumors can be observed in real time, so that a desired research model is provided for researching glioma based on in-situ transplanting and tracing of the human cerebral glioma and researching micro-environments of the tumors.

The invention discloses an antisense oligonucleotide used for inhibiting the expression of micro RNA-485-5p, and an application thereof. The antisense oligonucleotide comprises the sequence of 5'-GAAUUCAUCACGGCCAGCCUCU-3' which can be specifically combined with human miR-485-5p. The antisense oligonucleotide can be ribonucleotide, deoxyribonucleotide or chimera of the ribonucleotide and the deoxyribonucleotide, and can be used for modifying any nucleotide in the chain. The miR-485-5p antisense oligonucleotide can be used for effectively inhibiting the expression of miR-485-5p in a human brainglioma cell U87 as well as the growth and propagation of the human brain glioma cell U87, thus effectively treating the brain glioma and other tumours with high expression of miR-485-5p.

The invention relates to the field of medicine, in particular to a bionic nano medicament and a preparation method and application thereof. The nano medicament comprises an inner core and a shell withwhich the inner core is coated; the inner core comprises a first component, a second component and a carrier the side chain of which contains sensitive bonds; the shell comprises a cancer cell membrane. The carrier of the sensitive bonds stays in a weak acid environment and is rapidly swelled, an anti-cancer medicament TMZ and the second component are efficiently released, and the cancer cell membrane serving as the shell is made into the nano medicament, wherein the cancer cell membrane has certain self-recognition and high tumor selectivity for targeting in-vivo homologous homing tumors, and the in-vivo circulation time of the nano medicament can be greatly prolonged. The cancer cell membrane serving as the shell and the carrier of the sensitive bonds efficiently release the anti-cancermedicament TMZ and the second component, and finally tumor cells are killed, so that the purpose of targeted synergistic treatment of human brain gliomas is achieved.

The present invention discloses the application of toad venom extract containing more than 90% of bufolin, cinobufagin and cinobufagin in the preparation of medicines for treating human glioma. The content ratio of tobafagenin is 2:3:5, and the extract of toad venom is prepared into a nano-preparation. The bufagenin nano-preparation of the invention can increase the distribution of bufagenin in the brain and avoid being taken up by the heart, thereby improving the brain-targeting property of the drug and reducing cardiotoxicity. Compared with the common extract solution of bufogenin, the nano-preparation of bufogenin has a stronger therapeutic effect on glioma brain and less side effects, thus enhancing the use value of bufogenin and providing a new method for the treatment of glioma. new drug.

The invention belongs to the fields of biotechnology and medicine, in particular relates to an application of miR-29a as a novel brain glioma marker. The invention first validates that the expressions of the miR-29a in brain glioma tissues and cells are obviously decreased and the miR-29a acting as a tumor inhibiting gene is directly regulated and controlled by p53, and simultaneously first validates that p53 response genes such as MDM4, BCL2L2 and the like are direct targets of the miR-29a. Cytologic experiment proves that the miR-29a can obviously inhibit the propagation and infiltration of brain glioma cells, and animal in-vivo experiment proves that the miR-29a can inhibit the growth of the brain glioma. Besides, the further quantitative analysis of clinical brain glioma specimens of different levels shows that the miR-29a can be used as a brain glioma detection marker.

The invention relates to a new compound with remarkable antibacterial and antineoplastic activity, which has the following structure (shown in formula I), and has good antibacterial function for methicillin-resistant staphylococcus aureus (MRSA) and methicillin sensitive staphylococcus aureus (MSSA) as well as good antineoplastic function for human cervical cancer Hela cells, human liver cancer BEL-7402 cells, human mucinous epidermoid lung cancer A549 cells, human breast cancer MCF-7 / s cells and human glioma U251 cells. (In the formula I,) R=-CH3 or CF3, X=O, S or N, and R1=-Cl, -F, -CH3, -CF3, -OCH3 and -OCF3.

The present invention discloses a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. The invention also discloses a preparation method of the compound and application of the compound in prevention and / or treatment of cancers or tumor-related diseases, especially breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, human glioma and other diseases. The compound provided by the invention is expected to be developed into a new generation of anti-cancer drugs.

The invention provides application of zeylenone and derivatives thereof in preparation of anti-tumor drugs. The zeylenone is of a (+)-zeylenone configuration, and the molecular formula is shown as a formula (I). The derivative has a structure shown as a formula (II). The invention also provides a preparation method of zeylenone and the derivative thereof. The invention also provides application ofthe zeylenone and the derivative thereof or the zeylenone and the derivative thereof prepared by the preparation method of any one of the zeylenone and the derivative thereof in preparation of anti-tumor drugs. The tumor is selected from at least one of human brain glioma, human nasopharyngeal carcinoma, human liver cancer, human lung cancer, human neuroglioblastoma, human prostate cancer and mouse pancreatic cancer. The zeylenone and the derivative thereof are high in sensitivity and good in selectivity, and can be used for preparing anti-tumor drugs.